Understanding the Treatment Goals in Central Nervous System Melanoma

When melanoma reaches the central nervous system—which includes the brain and spinal cord—the treatment approach becomes more complex and requires careful coordination among different specialists. The main goals of treatment focus on controlling the cancer, reducing symptoms like headaches or neurological problems, slowing down the disease’s progression, and improving the patient’s quality of life. Treatment plans depend heavily on several factors: the stage of the disease, how many lesions are present in the brain, their size and location, whether the patient has symptoms, and the overall health condition of the individual.^[1]

Medical societies and expert groups have developed standard treatment approaches based on years of research and clinical experience. However, because this condition is challenging, doctors continue to explore new therapies through clinical trials. These ongoing research efforts test innovative drugs and treatment combinations that might work better than current options. The treatment field is rapidly evolving, particularly over the last decade, with eleven new drugs registered for advanced melanoma, significantly changing how doctors approach central nervous system involvement.^[6]

It’s important to understand that treatment for central nervous system melanoma typically involves two main strategies working together: local treatments that target specific tumors in the brain or spine, and systemic treatments that circulate throughout the body to fight cancer cells wherever they may be. Doctors now increasingly diagnose central nervous system metastases at earlier, symptom-free stages through routine brain imaging, which opens up more treatment possibilities and can lead to better outcomes.^[9]

Standard Treatment Approaches

Surgery and Local Interventions

Surgery plays an important role when melanoma forms one or a few accessible tumors in the brain. Neurosurgical resection, the surgical removal of brain tumors, can quickly relieve pressure on surrounding brain tissue and reduce symptoms. This approach works best when there are only a small number of metastases that can be safely reached without damaging critical brain areas. Doctors evaluate each patient individually to determine if surgery is appropriate, considering factors like the tumor’s location, the patient’s overall health, and whether the melanoma is controlled elsewhere in the body.^[1]

In studies examining outcomes, patients who underwent surgical removal of brain metastases followed by stereotactic radiosurgery (SRS) showed improved survival times. One analysis found that patients treated with resection and SRS had a median overall survival of 17.3 months, while those who had resection alone survived a median of 10 months. These numbers illustrate how combining different local treatments can work better than using just one approach.^[11]

Radiation Therapy Techniques

Stereotactic radiosurgery has become a cornerstone in treating brain metastases from melanoma. Despite its name, SRS is not actually surgery—it’s a highly precise form of radiation therapy that delivers focused beams to tumor sites while sparing surrounding healthy brain tissue. This technique allows doctors to treat multiple brain lesions in a single session or across a few sessions. The majority of brain metastases from melanoma are located in the upper part of the brain (supratentorial), with about 15 percent in the lower regions (infratentorial).^[1]

Research shows that SRS alone can be very effective. Patients who received SRS without surgical removal had a median overall survival of 17.4 months. Interestingly, the amount of tumor volume treated matters: patients with less than 2 cubic centimeters of tumor treated with SRS survived longer (20.5 months median) compared to those with more than 2 cubic centimeters treated (12 months median).^[11]

Whole brain radiotherapy (WBRT) used to be a standard treatment, but it’s now rarely used as the main approach because it can cause cognitive side effects and doesn’t necessarily improve survival compared to more targeted treatments like SRS. However, WBRT may still be considered in specific situations, such as when there are many small metastases throughout the brain.^[9]

Intrathecal Chemotherapy for Leptomeningeal Disease

When melanoma spreads to the leptomeninges—the delicate membranes surrounding the brain and spinal cord—it creates one of the most serious complications. Leptomeningeal metastases cause cancer cells to float in the cerebrospinal fluid that bathes the central nervous system. This condition is associated with extremely poor prognosis and limited treatment options.^[4]

For leptomeningeal disease, doctors may use intrathecal chemotherapy, where medication is injected directly into the cerebrospinal fluid space, usually through a lumbar puncture (spinal tap) or a surgically placed reservoir in the skull. Methotrexate is the most commonly used drug for this purpose. One documented case reported a patient receiving concurrent radiotherapy and weekly intra-cerebrospinal fluid methotrexate, followed by monthly methotrexate maintenance therapy, who survived 13 months after diagnosis—a relatively extended period given the severity of this complication.^[4]

Despite these efforts, intrathecal chemotherapy remains largely palliative, meaning it aims to relieve symptoms and slow progression rather than cure the disease. It doesn’t significantly increase survival but can help maintain quality of life during treatment.^[4]

Treatment in Clinical Trials

Immunotherapy: Harnessing the Body’s Immune System

The development of immunotherapy has revolutionized melanoma treatment, including cases with central nervous system involvement. These drugs work by removing the “brakes” on the immune system, allowing the body’s own defenses to recognize and attack cancer cells more effectively. Two main types of checkpoint inhibitor drugs have shown particular promise for brain metastases from melanoma.

Anti-PD-1 antibodies are monoclonal antibodies that block a protein called PD-1 (programmed death-1) on immune cells. This blockade prevents cancer cells from hiding from the immune system. Drugs in this class include nivolumab and pembrolizumab. Clinical experience shows that patients with brain metastases treated with anti-PD-1 therapy had a median overall survival of 14.1 months, which represents a significant improvement over historical outcomes with older treatments.^[11]

Ipilimumab works through a different mechanism, blocking CTLA-4 (cytotoxic T-lymphocyte antigen 4), another checkpoint protein. When used alone for patients with brain metastases, it achieved a median overall survival of 14.3 months. However, the real breakthrough came when researchers combined ipilimumab with nivolumab—an approach called dual immunotherapy.^[11]

Dual immunotherapy has emerged as the most effective systemic treatment option for melanoma brain metastases. Clinical trials testing the combination of ipilimumab and nivolumab demonstrated impressive results. In patients with asymptomatic brain metastases—meaning those who didn’t yet have neurological symptoms—the intracranial clinical benefit rate (a measure of how many patients’ brain tumors responded to treatment) reached 57 percent. Even more remarkably, the intracranial response rate was 58.4 percent in asymptomatic patients.^[11]

However, response rates dropped significantly in symptomatic patients—those already experiencing neurological problems from their brain metastases—with only 16.7 percent showing intracranial response. This difference highlights the importance of early detection and treatment before symptoms develop. Among patients who received first-line dual immunotherapy, the median overall survival reached an impressive 26.7 months, substantially longer than other treatment approaches.^[11]

It’s worth noting that immunotherapy can cause side effects because it activates the immune system broadly. These can include inflammation in various organs, fatigue, skin rashes, and diarrhea. More serious complications can occur but are less common. Doctors monitor patients closely during immunotherapy and can manage most side effects with additional medications when needed.

Targeted Therapy: BRAF and MEK Inhibitors

About 40 to 50 percent of melanomas carry a mutation in a gene called BRAF. This genetic change causes cancer cells to grow and divide uncontrollably. Scientists have developed drugs called BRAF inhibitors that specifically block the abnormal protein produced by this mutation, essentially turning off a key growth signal in cancer cells. Common BRAF inhibitors include vemurafenib, dabrafenib, and encorafenib.

These drugs are often combined with MEK inhibitors, which target a different protein in the same cellular pathway that promotes cancer growth. MEK inhibitors include trametinib, cobimetinib, and binimetinib. The combination works better than either drug alone because it blocks the cancer growth pathway at two different points, making it harder for cancer cells to develop resistance.^[1]

Clinical studies have shown that BRAF and MEK inhibitor combinations have activity against brain metastases. These drugs have the advantage of being oral medications taken at home, unlike immunotherapy which is typically given by infusion in a clinic. Patients with central nervous system disease treated with kinase inhibitors (the broader category that includes BRAF and MEK inhibitors) had a median overall survival of 10.9 months.^[11]

One important consideration is that BRAF and MEK inhibitors only work in patients whose melanomas have the BRAF mutation. Genetic testing of the tumor—called molecular profiling or biomarker testing—is essential before starting these therapies. The drugs have no effect on melanomas without this particular mutation, which is why testing is a critical first step in treatment planning.

Side effects of targeted therapy can include fever, fatigue, skin problems, joint pain, and changes in heart function. Most side effects are manageable with dose adjustments or supportive medications. Unlike immunotherapy, these drugs typically need to be taken continuously for as long as they’re working.

Current Clinical Trial Investigations

Researchers continue to investigate new approaches in clinical trials, which represent the pathway for bringing tomorrow’s treatments to patients today. Clinical trials proceed through several phases, each with specific purposes.

Phase I trials primarily assess safety. Researchers determine the appropriate dose of a new drug and identify what side effects occur and at what frequency. These trials enroll small numbers of patients and carefully monitor their responses. Phase I trials are crucial for establishing whether a new approach is safe enough to test in larger groups.

Phase II trials focus on efficacy—whether the treatment actually works against the cancer. These studies enroll more patients and measure response rates, how long responses last, and continue monitoring safety. Phase II trials help researchers decide if a treatment is promising enough to move forward to larger comparative studies.

Phase III trials are large comparative studies that test new treatments against current standard treatments. These trials provide the strongest evidence about whether a new approach is better than existing options. Successful Phase III trials typically lead to regulatory approval and widespread availability of new treatments.

Current areas of investigation for central nervous system melanoma include testing whether combining immunotherapy with radiation therapy works better than either treatment alone, studying new checkpoint inhibitors that target different immune pathways, exploring optimal timing and sequencing of various treatments, and developing better ways to deliver drugs across the blood-brain barrier—a protective barrier that normally prevents many substances from entering brain tissue but also blocks some cancer medications.^[3]

Clinical trials are conducted at major medical centers across the United States, Europe, and other regions. Eligibility criteria vary by study but typically consider factors like disease stage, previous treatments received, genetic characteristics of the tumor, overall health status, and specific features of the brain metastases such as size, number, and whether they’re causing symptoms. Patients interested in clinical trials should discuss options with their treatment team.^[6]

Most common treatment methods

• Surgical approaches
  • Neurosurgical resection removes accessible brain tumors and can quickly relieve symptoms caused by tumor pressure
  • Surgery combined with stereotactic radiosurgery shows improved survival compared to surgery alone
  • Best suited for patients with a limited number of brain metastases in accessible locations
• Radiation therapy
  • Stereotactic radiosurgery delivers highly focused radiation to brain tumors while sparing healthy tissue
  • Can treat multiple brain lesions in one or a few sessions
  • Patients with smaller tumor volumes treated with SRS show better survival outcomes
  • Whole brain radiotherapy is now rarely used as first-line treatment due to cognitive side effects
• Immunotherapy
  • Anti-PD-1 antibodies (nivolumab, pembrolizumab) block immune checkpoints and allow the body to attack cancer cells
  • Ipilimumab targets CTLA-4, a different immune checkpoint protein
  • Dual immunotherapy combining ipilimumab and nivolumab shows the highest survival rates, especially in asymptomatic patients
  • Intracranial response rates reach 58.4 percent in patients without neurological symptoms
• Targeted therapy
  • BRAF inhibitors block abnormal proteins in melanomas with BRAF gene mutations
  • MEK inhibitors target a related protein in the same cancer growth pathway
  • Combination BRAF plus MEK inhibitor therapy works better than single-agent treatment
  • Only effective in patients whose tumors carry the BRAF mutation, requiring genetic testing before treatment
• Intrathecal chemotherapy
  • Methotrexate injected directly into cerebrospinal fluid for leptomeningeal metastases
  • Can be given weekly initially, then monthly as maintenance therapy
  • Combined with radiotherapy in some treatment protocols
  • Primarily palliative, aiming to control symptoms rather than cure disease